RWJ 442831

Drug Profile

RWJ 442831

Alternative Names: RWJ-442831

Latest Information Update: 29 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Essential Therapeutics [CEASED]
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC
  • Class Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections pharmacodynamics section
  • 04 Oct 2004 Essential Therapeutics has closed down
  • 24 Sep 2003 Preclinical data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the pharmacokinetics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top